Cost-Effectiveness of Telisotuzumab Vedotin-tllv for Previously Treated High c-Met Protein-Overexpressing Nonsquamous Non-Small Cell Lung Cancer in the United States

Value in Health · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles